Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.46 |
| ▸ | PDE5A | O76074 | 12/20 | 0.45 |
| ▸ | PRUNE1 | Q86TP1 | 1/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.41 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30113064 | 0.90 | PDE5A (0.45) | SLC29A1PDE5APRUNE1CCNE2CCNE1 | |
| SCHEMBL25188426 | 0.90 | PDE5A (0.45) | SLC29A1PDE5APRUNE1CCNE2CCNE1 | |
| SCHEMBL25196808 | 0.89 | PRUNE1 (0.56) | SLC29A1PDE5APRUNE1CCNE2CCNE1 | |
| SCHEMBL25184648 | 0.89 | SLC29A1 (0.50) | SLC29A1PRUNE1CCNE2CCNE1CDK2 | |
| SCHEMBL30112885 | 0.88 | PDE5A (0.46) | SLC29A1PDE5APRUNE1CCNE2CCNE1 | |
| SCHEMBL30113097 | 0.88 | SLC29A1 (0.43) | SLC29A1PDE5APRUNE1CCNE2CCNE1 | |
| SCHEMBL25214065 | 0.88 | SLC29A1 (0.43) | SLC29A1PDE5APRUNE1CCNE2CCNE1 | |
| SCHEMBL25195012 | 0.88 | PDE5A (0.46) | SLC29A1PDE5APRUNE1CCNE2CCNE1 | |
| SCHEMBL25190660 | 0.88 | SLC29A1 (0.49) | SLC29A1PDE5APRUNE1CCNE2CCNE1 | |
| SCHEMBL25190634 | 0.87 | PRUNE1 (0.43) | SLC29A1PDE5APRUNE1CCNE2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | claimed |
| EP-4110784-A1 | PYRIMIDO[5,4-D]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-01-04 | — | — | EP | claimed |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD5, ENTPD1, SLC29A1 | SLC29A1 3/4885PDE5A 1707/4885PRUNE1 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.